Zapping away cancer's lingering side effects: NESA device tested on survivors
NCT ID NCT06230679
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study tested a non-invasive device called NESA that gently stimulates nerves to help cancer survivors with sleep problems, fatigue, and muscle pain. Forty survivors who had finished cancer treatment at least five years ago took part. The goal was to see if the device could improve their quality of life by easing these common late effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NESA non-invasive neurostimulation device
- What this could lead to
- If it works, this could offer a drug-free option to ease common late effects of cancer treatment, improving quality of life for survivors.
- What could go wrong
- This is a small, completed trial with only 40 participants. Results may not apply to all survivors, and the placebo effect could play a role.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be a cancer survivor (5 years after discharge) * Have 1 of the 3 symptoms of the most common cluster: sleep problems, chronic fatigue, chronic neuro-muscular pain. Exclusion Criteria: * Not have an active oncological process * Present any of the contraindications of the NESA-XSignal device: pacemaker, internal bleeding, skin in poor condition (ulcerations or wounds), acute febrile processes, acute thrombophlebitis, pregnancy, phobia of electricity.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer survivors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gutmotion
Santa Maria del Camí, Balearic, 07320, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple activity-based therapy lift depression in older cancer survivors?
- Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
- Digital exercise program aims to boost recovery for breast cancer survivors
- Fitbit and app aim to boost activity in cancer survivors
- Online workouts may rebuild bones in childhood cancer survivors
- Can a phone app slow kidney disease? new trial aims to find out